Collaboration enables direct integration of DataHow’s digital solutions with Genedata’s platform, accelerating the development of next-generation biotherapeutics

BASEL and Zürich, Switzerland, September 12, 2022 /PRNewswire-PRWeb/ –Genedata and DataHow, two leading innovators for the digital transformation of biopharmaceutical R&D, have entered into a strategic partnership to integrate their platforms to further streamline bioprocess development and manufacturing workflows. The combined solution will directly integrate DataHow’s Digital Twin products, including DataHowLab and SpectraHow, with the Genedata Biopharma platform so that process development and manufacturing data can be exchanged and interpreted seamlessly. The joint availability of experimental data and modeling data will streamline digitization across the development and manufacturing of biopharmaceutical processes. This will enable digital data tracking for every molecule, sample, and process for more efficient process development and incorporate state-of-the-art modeling capabilities to better understand and optimize critical attributes of the biopharmaceutical manufacturing process.

DataHow’s platform provides high performance bioprocess data analysis and predictive modeling tools based on a user-friendly workflow with custom data visualization techniques, hybrid modeling for process understanding and design, and machine learning to enable self-learning capabilities and knowledge transfer between molecules and Libra. Genedata Bioprocess® is a fully integrated biopharmaceutical R&D workflow platform that integrates processes and connects people, data and laboratory instruments to automate enterprise-wide development and manufacturing operations. It supports the entire end-to-end (E2E) process, covering Cell Line Development (CLD), Upstream Process Development (USP), Downstream Process Development (DSP), Formulation (FD), Process Analytical Support and Analytical Development (UN D). The integration of the platforms creates synergies that promote harmonization and automation throughout the process. Additionally, as part of the collaboration, DataHow and Genedata will extend the integrated platform to other areas of innovation in process development and manufacturing, including process monitoring and control supported by a hybrid model with Raman spectroscopy and E2E applications of Digital Twins.

“The development of innovative biotherapies, including cell and gene therapies and next-generation vaccines, relies on extremely complex and data-rich R&D processes,” noted Othmar Pfannes, Ph.D., CEO of Genedata. “The Genedata Biopharma Platform enables full automation of experimental workflows through its flexible data model and open programming interfaces. It also enables emerging technology leaders such as DataHow to integrate their technology platform, minimizing configuration and integration work for joint customers and directly creating value from the data generated.This integration offers the best of both worlds: fully automated high-throughput processes complemented by a comprehensive modeling platform enabling faster and more efficient decision making for process development and manufacturing.”

“Complete digitization of production processes is at the heart of DataHow’s vision. Digitization will enable users to perform a vast majority of tasks related to silico and automated manufacturing processes. This includes predictive process monitoring, optimization, scenario and deviation analysis and quality management,” said Alessandro Butté, CEO of DataHow AG. “Both companies share a common vision: to provide the biopharmaceutical industry with a holistic platform that communicates seamlessly between all involved stakeholders, enabling the management of bioprocess data and knowledge in an understandable digital format. Our collaboration with Genedata will streamline the entire biopharmaceutical lifecycle from process development to late-stage manufacturing.”

About DataComment
DataHow is a software provider focused on accelerating process development, optimizing manufacturing processes, and increasing robustness using hybrid modeling solutions. Our software and services are suitable for upstream (cell culture, fermentation, seed train, etc.) and downstream (chromatography, ultrafiltration, diafiltration, etc.) biopharmaceutical operations, providing the user with essential information for development, characterization and scaling up of processes. . Our unique Digital Twin technology manages all process units and their interactions, and transfers knowledge between scales, projects and product targets. With our approach, we want to support the decision-making process of process experts, scientists and operators by using all available data and process knowledge in our technology. DataHow was incorporated in 2017 as a spin-off from ETH Zurich and operates with 45 team members on 3 continents.
http://www.datahow.ch
LinkedIn

About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate in-depth knowledge of the field of biopharmaceutical R&D. Multinational biopharmaceutical organizations and cutting-edge biotechs around the world rely on Genedata to digitize and automate complex, data-rich R&D processes. From early discovery through to the clinic, Genedata solutions help maximize the return on investment of R&D expenditures. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices Boston, London, Munich, San Francisco, Singaporeand Tokyo.
http://www.genedata.com
LinkedIn| Twitter| Youtube
________________________________________
Contact
Allison Kurz
Genedata
Public relations
[email protected]

Disclaimer
Statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, factors uncertainties relating to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events.

All product and service names mentioned are trademarks of their respective companies.

Media Contact

Allison KurzGenedata, +41615118459, [email protected]

SOURCE Genedata